Trials / Recruiting
RecruitingNCT06197139
A Clinical Study of [177Lu]Lu-XT117 Injection in Patients With Advanced Solid Tumors
A Clinical Study to Evaluate the Safety, Tolerability, Dosimetry and Preliminary Efficacy of [177Lu]Lu-XT117 Injection in FAP-positive Patients With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Xinlu Wang · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-center, single-arm clinical study to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[177Lu\]Lu-XT117 injection in patients with FAP-positive advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [177Lu]Lu-XT117 | \[177Lu\]Lu-XT117 is a radiopharmaceutical therapy in which an beta emitter, Lu-177, is conjugated to XT117. Patients will receive \[177Lu\]Lu-XT117 administration at an interval of 6 weeks between each dose. |
Timeline
- Start date
- 2024-01-01
- Primary completion
- 2025-12-01
- Completion
- 2026-12-01
- First posted
- 2024-01-09
- Last updated
- 2024-01-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06197139. Inclusion in this directory is not an endorsement.